ITM And POINT Biopharma Expand Global Supply Agreement for N.C.A. Lutetium-177
Portfolio Pulse from Benzinga Newsdesk
ITM and POINT Biopharma have expanded their global supply agreement for N.C.A. Lutetium-177. This expansion will allow for a more robust supply chain and increased production capabilities.
July 31, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The expanded agreement with ITM will allow POINT Biopharma to increase its production capabilities and strengthen its supply chain for N.C.A. Lutetium-177.
The expanded agreement with ITM will allow POINT Biopharma to increase its production capabilities. This could lead to increased revenues and profitability in the future, which is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100